These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7610691)

  • 1. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
    Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Crohn disease: prevention and drug therapy].
    Gross V; Andus T; Schölmerich J
    Chirurg; 1995 Aug; 66(8):757-63. PubMed ID: 7587538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
    de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
    Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
    Rutgeerts P
    Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
    Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
    Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy.
    Ecker KW; Stallmach A; Löffler J; Greinwald R; Achenbach U
    Dis Colon Rectum; 2005 Feb; 48(2):237-42. PubMed ID: 15714248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease.
    Tillinger W; Gasche C; Reinisch W; Lichtenberger C; Bakos S; Dejaco C; Moser G; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1998 Oct; 93(10):1848-53. PubMed ID: 9772043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
    Andus T; Gross V; Caesar I; Schulz HJ; Lochs H; Strohm WD; Gierend M; Weber A; Ewe K; Schölmerich J;
    Dig Dis Sci; 2003 Feb; 48(2):373-8. PubMed ID: 12643618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization.
    Herfarth H; Gross V; Andus T; Caesar I; Vogelsang H; Adler G; Malchow H; Petri A; Gierend M; Schölmerich J;
    Int J Colorectal Dis; 2004 Mar; 19(2):147-52. PubMed ID: 13680283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral budesonide in active Crohn's disease.
    Löfberg R; Danielsson A; Salde L
    Aliment Pharmacol Ther; 1993 Dec; 7(6):611-6. PubMed ID: 8161666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.